[{"orgOrder":0,"company":"Thryv Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Undisclosed","year":"2022","type":"Not Applicable","leadProduct":"Undisclosed","moa":"SGK1","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Thryv Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Thryv Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Thryv Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Thryv Therapeutics","sponsor":"Investissement Qu\u00e9bec","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2023","type":"Financing","leadProduct":"Islasertib","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Thryv Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.01,"dosageForm":"","sponsorNew":"Thryv Therapeutics \/ Investissement Qu\u00e9bec","highestDevelopmentStatusID":"6","companyTruncated":"Thryv Therapeutics \/ Investissement Qu\u00e9bec"},{"orgOrder":0,"company":"Thryv Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Islasertib","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Thryv Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Thryv Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Thryv Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Thryv Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Dofetilide","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Thryv Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Thryv Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Thryv Therapeutics \/ Not Applicable"}]